Learning Objectives

Journal Review “Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis” Ytterberg et al., 2022, The New England Journal of Medicine 386 (4), 316-326

1. To discuss and learn about potential cardiovascular and cancer risk associated with tofacitinib

2. To improve critical analysis of a peer-reviewed journal article


Session date: 
03/22/2022 - 9:30am to 10:30am CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Kichul Ko, M.D.